INHC vs. RENX, COG, TRLS, IQAI, FDBK, DVRG, SENS, EMIS, CRW, and INS
Should you be buying Induction Healthcare Group stock or one of its competitors? The main competitors of Induction Healthcare Group include Renalytix (RENX), Cambridge Cognition (COG), Trellus Health (TRLS), IQ-AI (IQAI), Feedback (FDBK), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.
Induction Healthcare Group vs.
Induction Healthcare Group (LON:INHC) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
Induction Healthcare Group has a net margin of -40.70% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Induction Healthcare Group's return on equity.
In the previous week, Induction Healthcare Group had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Induction Healthcare Group and 0 mentions for Renalytix. Induction Healthcare Group's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.
Renalytix received 9 more outperform votes than Induction Healthcare Group when rated by MarketBeat users. However, 93.33% of users gave Induction Healthcare Group an outperform vote while only 74.19% of users gave Renalytix an outperform vote.
Induction Healthcare Group has a beta of -0.41, suggesting that its share price is 141% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
Induction Healthcare Group has higher revenue and earnings than Renalytix. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
46.3% of Induction Healthcare Group shares are held by institutional investors. Comparatively, 28.4% of Renalytix shares are held by institutional investors. 54.6% of Induction Healthcare Group shares are held by company insiders. Comparatively, 35.7% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Induction Healthcare Group beats Renalytix on 9 of the 14 factors compared between the two stocks.
Get Induction Healthcare Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for INHC and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Induction Healthcare Group Competitors List
Related Companies and Tools
This page (LON:INHC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free INHC Stock Alerts